Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online
55,000 vials of peptides will be produced from this production suite and are pre-sold Milestone facility meets cGMP, FDA, and ISO quality standards on schedule; remaining three suites to launch in September MEQUON, Wis., Aug. 24, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp....
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


